Current Fungal Infection Reports

, Volume 5, Issue 2, pp 103–110

Antifungal Therapy in Pediatric Patients

  • Thomas Lehrnbecher
  • Konrad Bochennek
  • Dominik Schrey
  • Andreas H. Groll
Article

DOI: 10.1007/s12281-011-0046-x

Cite this article as:
Lehrnbecher, T., Bochennek, K., Schrey, D. et al. Curr Fungal Infect Rep (2011) 5: 103. doi:10.1007/s12281-011-0046-x
  • 95 Downloads

Abstract

Invasive fungal infections still play a major role in morbidity and mortality in pediatric patients, especially in children undergoing therapy for an underlying malignancy and in preterm infants. Relative to the adult population, pediatric age groups display important differences not only in host biology, predisposing conditions, epidemiology, and presentation of fungal infections, but also in the disposition and clearance of antifungal compounds. During the past decade, several new antifungal agents have been developed. Although not all of these agents are yet approved for children, the pediatric development of antifungal agents has moved forward in an exemplary manner, which is essential for the successful management of the individual patient. This article reviews the current data on pharmacokinetics, safety, and dosing of antifungal agents in pediatric patients.

Keywords

Child Neonate Preterm Invasive fungal infection Amphotericin B deoxycholate Lipid formulations of amphotericin B Fluconazole Itraconazole Voriconazole Posaconazole 5-Fluorocytosine Anidulafungin Caspofungin Micafungin 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Thomas Lehrnbecher
    • 1
  • Konrad Bochennek
    • 1
  • Dominik Schrey
    • 2
  • Andreas H. Groll
    • 2
  1. 1.Pediatric Hematology and Oncology, Children’s Hospital IIIJohann Wolfgang Goethe-UniversityFrankfurtGermany
  2. 2.Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/OncologyUniversity Children’s Hospital MuensterMuensterGermany